- OncoSec Medical (NASDAQ:ONCS) has entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of TAVO with Keytruda in a global late-stage trial.
- OncoSec shares up more than 20% post market.
- The trial will evaluate the overall survival of patients treated with the combination versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.
- It intends to enroll about 400 patients and is planned to be conducted in the U.S., Canada, EU, and Australia.
- TAVO is OncoSec's DNA-plasmid interleukin-12 (IL-12), while Keytruda is Merck's blockbuster cancer drug.